Publications by authors named "Nabeel Mangadan Konath"
Introduction: Key populations (sex workers, men who have sex with men, people who inject drugs, people in prisons and other closed settings, and trans and gender diverse individuals) are disproportionately affected by HIV, sexually transmitted infections (STIs) and viral hepatitis (VH). Counselling behavioural interventions are widely used, but their impact on HIV/STI/VH acquisition is unclear.
Methods: To inform World Health Organization guidelines, we conducted a systematic review and meta-analysis of effectiveness, values and preferences, and cost studies about counselling behavioural interventions with key populations.
Background: The World Health Organization (WHO) recommends oral pre-exposure prophylaxis (PrEP) for all people at substantial risk of HIV as part of combination prevention. The extent to which this recommendation has been implemented globally for people who inject drugs is unclear. This study mapped global service delivery of PrEP for people who inject drugs.
View Article and Find Full Text PDFBackground: This systematic review was aimed to estimate hepatitis C virus (HCV) seroprevalence and burden in disease in WHO South East Asia Region (SEAR).
Methods: Electronic databases (PubMed, Scopus, Embase, and Google Scholar) and websites of non-indexed national medical journals, government and international health agencies were searched to identify English language literature published between 1991 and June 2020. We selected the studies reporting HCV seroprevalence in asymptomatic general (low-risk) and high-risk adult populations, that is, persons living with HIV (PLHIV), persons who inject drugs (PWID), sex workers, persons on maintenance hemodialysis (MHD), people in prison, and men sex with men (MSM).
In 2016, Asia and Pacific countries endorsed action plans for reaching viral hepatitis elimination targets set in the Global Health Sector Strategy (GHSS) for Viral Hepatitis 2016-2021. We examine the region's progress by modelling disease burden and constructing the cascade of care. Between 2015 and 2020, chronic HBV prevalence declined from 4.
View Article and Find Full Text PDFArticle Synopsis
- - From 2016 to 2019, the adoption of WHO PrEP guidelines saw significant growth, with 67% of surveyed countries implementing these recommendations, increasing the number of PrEP users from around 370,000 to 626,000 in just one year.
- - By analyzing data from various regions, it was forecasted that global PrEP users could reach between 2.4 million and 5.3 million by the end of 2023, although potential disruptions from COVID-19 could lower this estimate to between 2.1 million and 3 million.
- - The findings highlight the successful uptake of PrEP in many countries but also underline the uncertainty introduced by the pandemic, emphasizing the need for
Impact of COVID-19 on the global supply chain of antiretroviral drugs: a rapid survey of Indian manufacturers.
WHO South East Asia J Public Health
September 2020
Most people living with HIV in low- and middle-income countries are treated with generic antiretroviral (ARV) drugs produced by manufacturers in India - the "pharmacy of the developing world". India's nationwide lockdown in March 2020 in response to the coronavirus disease 2019 (COVID-19) pandemic therefore prompted concerns about disruption to this essential supply. A preliminary assessment of ARV drug manufacturers in India in March 2020 indicated a range of concerns.
View Article and Find Full Text PDF